TAT-D1 peptide 是一种多巴胺 D1-D2 受体异源二聚体抑制剂,可破坏多巴胺 D1-D2 受体异聚体的功能,增强亚慢性苯丙胺诱导的自主活动并加剧苯丙胺诱导的自主活动敏化的表达,在抑郁焦虑大鼠模型中产生快速的抗焦虑和抗抑郁样效应并抑制大鼠伏隔核中 c-fos 表达,可用于精神兴奋剂成瘾、抑郁症和焦虑症的研究。
TAT-D1 peptide
产品编号: MS-T95760 分子式: C144H257N57O43 分子量: 3474.94
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

TAT-D1 peptide 是一种多巴胺 D1-D2 受体异源二聚体抑制剂,可破坏多巴胺 D1-D2 受体异聚体的功能,增强亚慢性苯丙胺诱导的自主活动并加剧苯丙胺诱导的自主活动敏化的表达,在抑郁焦虑大鼠模型中产生快速的抗焦虑和抗抑郁样效应并抑制大鼠伏隔核中 c-fos 表达,可用于精神兴奋剂成瘾、抑郁症和焦虑症的研究。

生物实验数据

生物活性 TAT-D1 peptide is a dopamine D1-D2 receptor heterodimer inhibitor that disrupts the function of dopamine D1-D2 receptor heteromers, enhances subchronic amphetamine-induced locomotor activity and exacerbates the expression of amphetamine-induced locomotor sensitization, produces rapid anxiolytic and antidepressant-like effects in rat models of depression and anxiety while inhibiting c-fos expression in the rat nucleus accumbens, and can be used for research on psychostimulant addiction, depression, and anxiety.
体内研究
(In Vivo)

TAT-D1 peptide (i.c.v.;注射前 15 分钟;连续 5 天每日给药;单剂量,300 pM) 可破坏多巴胺 D1-D2 受体异聚体的功能,增强亚慢性苯丙胺诱导的自主活动,并加剧苯丙胺诱导的自主活动敏化的表达。
TAT-D1 peptide (i.c.v.;单剂量,300 pM) 可通过缩短强迫游泳实验中的总不动时间,在未受应激的大鼠中发挥类抗抑郁作用;通过增加高架十字迷宫中大鼠进入开臂的停留时间、缩短新奇摄食抑制实验中的摄食潜伏期,发挥类抗焦虑作用,逆转 CUS 暴露大鼠的快感缺失性蔗糖偏好降低、完全逆转 CUS 诱导的新环境进食潜伏期延长以及增加水果圈摄入量,发挥快速的抗抑郁作用,可抑制 SKF 83959 (MS-T86581) 诱导的伏隔核 c-fos 表达及 SKF 83959 诱导的理毛行为,而单独给药可在皮质、前嗅区、外侧缰核和丘脑区域诱导区域特异性 c-fos 表达。

Animal Model: Sprague-Dawley (adult male, 300-350 g)
Dosage: 300 pM (acute pre-administration; co-administration; repeated administration)
Administration: intracerebroventricular (i.c.v.); 15 minutes prior to injection; daily for 5 consecutive days; single dose
Result: Elevated total 60-minute locomotor activity to 2918.1 beam breaks, a significant increase compared to saline controls.
Induced a robust locomotor increase in the first 5 minutes post-injection that was significantly higher than controls.
Did not produce a significant change in locomotor activity in non-habituated rats compared to vehicle controls.
Significantly enhanced locomotor responsiveness to amphetamine across the 5-day regimen compared to amphetamine alone (p < 0.05).
Induced a sensitized locomotor response to the priming amphetamine injection with total 60-minute activity of 7337.0 ± 920.4 beam breaks, significantly higher than saline-pretreated controls and comparable to amphetamine-sensitized rats.
Further enhanced the sensitized locomotor response to the priming amphetamine injection with total 60-minute activity of 8989.3 beam breaks, significantly higher than both saline-pretreated controls and amphetamine-sensitized rats.
Did not alter the expression of locomotor sensitization in amphetamine-sensitized rats, with total 60-minute activity of 7948.5 beam breaks, significantly higher than saline-pretreated controls.
Animal Model: Sprague-Dawley (adult male, 300-400 g); Fischer 344 (adult male, 300-400 g, chronic unpredictable stress model)
Dosage: 300 pM
Administration: i.c.v.; single dose
Result: Significantly reduced total immobility timein forced swim test.
Significantly increased time spent in open arms per entryand reduced total open arm entriesin elevated plus maze.
Significantly reduced latency to drink milk in novel environment in novelty-induced hypophagia test.
Abolished SKF 83959-induced reduction in latency to immobility and increase in immobility within first minute of forced swim test.
Abolished SKF 83959-induced reduction in time spent in open arms per entry and total time spent in open arms in elevated plus maze.
Robustly attenuated SKF 83959-induced enhanced latency to drink milk and reinstated total milk consumption in novelty-induced hypophagia test.
Partially reversed CUS-induced reduction in sucrose preference scores, eliminating significant difference between CUS-exposed and non-exposed control rats.
Completely reversed CUS-induced increase in latency to consume fruit loops to non-stressed control levels; significantly increased total fruit loops consumed in CUS-exposed and non-exposed control rats.
Completely abolished CUS-induced prolongation of feeding latency in novel environment, restoring latency to non-stressed control levels.
Showed no significant effect on total time spent in open arms in elevated plus maze.
Significantly reduced SKF 83959-induced c-fos expression in nucleus accumbens (NAc) core and NAc shell.
Abolished SKF 83959-induced grooming behavior, reducing grooming time.
Induced significant c-fos expression in multiple brain regions when administered standalone: anterior olfactory nucleus, orbitofrontal cortex, infralimbic cortex, prelimbic cortex, piriform cortex, lateral habenula, thalamic nuclei.
Showed no effect on c-fos expression in striatal subregions, ventral pallidum, globus pallidus, lateral hypothalamus, hippocampus, amygdala, substantia nigra, ventral tegmental area, or rostromedial tegmental nucleus when administered standalone.

化学信息

分子量 3474.94
分子式 C144H257N57O43

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础